AbbVie sees a megablockbuster in Vraylar. Could a new depression indication push peak sales past $4B?

Despite a bumpy takeoff, AbbVie has some big plans for Vraylar, the blockbuster schizophrenia and bipolar drug it snapped up from Allergan a couple of years ago. Looking ahead, CEO Richard Gonzalez says a supplemental approval in major depressive disorder could send sales into the stratosphere — that is, if the FDA is willing to get on board.